89Zr-DFO-Atezolizumab for Kidney Cancer

UT Southwestern Medical Center, Dallas, TX
Kidney Cancer89Zr-DFO-Atezolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will explore whether a new imaging scan can predict how well a patient with renal cell carcinoma will respond to immunotherapy.

Eligible Conditions
  • Kidney Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase < 1

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Up to 5 years

Up to 5 years
Correlation between 89Zr-DFO-Atezolizumab and PD-L1
Correlation between 89Zr-DFO-Atezolizumab and anti-PD1/PD-L1 therapy

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2 Treatment Groups

Cohort 1
1 of 2
Cohort 2
1 of 2

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: 89Zr-DFO-Atezolizumab · No Placebo Group · Phase < 1

Cohort 1Experimental Group · 2 Interventions: 89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography · Intervention Types: Drug, Procedure
Cohort 2Experimental Group · 2 Interventions: 89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography · Intervention Types: Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography/Computed Tomography
2020
Completed Phase 2
~20

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

James BrugarolasLead Sponsor
Orhan Kemal OzLead Sponsor
1 Previous Clinical Trials
80 Total Patients Enrolled
Orhan Oz, MD, PhDPrincipal InvestigatorUT Southwestern Medical Center
James Brugarolas, MD, PhDPrincipal InvestigatorUT Southwestern Medical Center
1 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be able to lie still for 30 to 60 minutes during a PET/CT scan.

Frequently Asked Questions

What medical condition is 89Zr-DFO-Atezolizumab typically employed to address?

"89Zr-DFO-Atezolizumab has been demonstrated to be efficacious in the treatment of small cell lung cancer (sclc), malignant neoplasms, and non-small cell lung carcinoma." - Anonymous Online Contributor

Unverified Answer

To what extent is participation in this clinical trial being observed?

"Indeed, clinicaltrials.gov verifies that this medical study is in the process of recruiting participants. It was first posted on October 2nd 2019 and its most recent update occurred on August 2nd 2022. 40 patients are needed to complete enrollment at a single centre." - Anonymous Online Contributor

Unverified Answer

Is this the inaugural iteration of this clinical experiment?

"Research into 89Zr-DFO-Atezolizumab began in 2008 with a clinical trial funded by Hoffmann La Roche. After positive outcomes from the first study of 720, this drug was granted Phase 2 approval and is now being evaluated in 348 studies located across 74 different nations." - Anonymous Online Contributor

Unverified Answer

Are individuals currently being accepted to participate in this research?

"According to clinicaltrials.gov, this medical study is currently in recruitment mode. It was initially posted on October 2nd 2019 and the last update came on August 2nd 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.